美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Emera Inc.

49.28

-0.1000-0.20%

盤後：49.280.00000.00%19:30 EDT

成交量：38.15萬

成交額：1,875.92萬

市值：150.69億

市盈率：22.10

高：49.32

開：48.96

低：48.66

收：49.38

52周最高：55.49

52周最低：45.78

股本：3.06億

流通股本：3.06億

量比：1.45

換手率：0.12%

股息：2.09

股息率：4.24%

每股收益(TTM):2.23

每股收益(LYR):2.47

淨資產收益率：7.56%

總資產收益率：2.91%

市淨率：1.63

市盈率(LYR):19.99

資料載入中...

總覽公司新聞資訊公告

數十名患者起訴司美格魯肽製造商

伯維（ABBV）向EMA遞交Skyrizi克羅恩病治療上市申請

中化國際EMA項目投產

分析師：比特幣已觸及長期下行趨勢線及 21 個月 EMA 均線，站穩當前阻力線方能確認漲勢

奧麥羅斯2026財年第二季度業績：YARTEMLEA推動運營實現收支平衡

TradingKey中文

Emera（EMA）上半年調整後淨利潤增至6.27億加元、淨收入降至6.67億加元

財報前瞻｜Emera Inc.本季度營收預計增15.89%，機構觀點偏謹慎

瑞博生物-B：核心產品VORTOSIRAN針對SPAF的2B期臨床試驗獲EMA批准

歐洲藥品管理局（EMA）：阿斯利康(AZN.US)已撤回其重磅免疫藥物Imfinzi在歐盟的擴展適應症申請。

Rocket Lab股價站穩200日EMA上方：獲NASA合同後是否值得買入？

环球市场播报

恒瑞醫藥(600276.SH)：瑞維魯胺片上市許可申請獲EMA受理

新聞稿：CosmoFarm公布2026年第二季度創紀錄營收超1500萬美元，年化運行率超6000萬美元；新增超80家藥房並擴展AI自動化與設施產能

從跟隨者到定價者：加密市場的角色正在反轉

財報前瞻｜Emera Inc.本季度營收預計增35.49%，盈利質量成看點

羅氏獲歐洲監管機構反饋後，啓動Elevidys基因療法新研究

环球市场播报

港股異動 | 和譽-B(02256)盤中漲近10% FGFR4抑制劑依帕戈替尼獲EMA授予孤兒藥資格

和譽-B(02256)：FGFR4抑制劑依帕戈替尼獲EMA授予孤兒藥資格，用於治療肝細胞癌

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/EMA/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"EMA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","market":"US","secType":"STK","nameCN":"Emera Inc.","latestPrice":49.28,"timestamp":1789761600000,"preClose":49.38,"halted":0,"volume":381479,"hourTrading":{"tag":"盘后","latestPrice":49.28,"preClose":49.28,"latestTime":"19:30 EDT","volume":40384,"amount":1992699.06912,"timestamp":1789774206298,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.0020251113811259906,"floatShares":305783111,"shares":305783111,"eps":2.229761,"marketStatus":"休市中","change":-0.1,"latestTime":"09-18 16:00:00 EDT","open":48.96,"high":49.32,"low":48.66,"amount":18759191.6771,"amplitude":0.013366,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.229761,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789977600000},"marketStatusCode":7,"adr":0,"exchange":"NYSE","adjPreClose":49.38,"dividendRate":0.042791,"postHourTrading":{"tag":"盘后","latestPrice":49.28,"preClose":49.28,"latestTime":"19:30 EDT","volume":40384,"amount":1992699.06912,"timestamp":1789774206298,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.4540410074543813,"impliedVol":0.4231,"impliedVolPercentile":0.9761},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","floatShares":305783111,"roa":"2.91%","roe":"7.56%","lyrEps":2.465138,"volumeRatio":1.4540410074543813,"shares":305783111,"dividePrice":2.087723,"high":49.32,"amplitude":0.013366,"preClose":49.38,"low":48.66,"week52Low":45.78,"pbRate":"1.63","psRate":"2.36","week52High":55.49,"institutionHeld":0,"latestPrice":49.28,"eps":2.229761,"divideRate":0.042365,"volume":381479,"delay":0,"ttmEps":2.229761,"open":48.96,"prevYearClose":49.24,"prevWeekClose":49.19,"prevMonthClose":50.09,"prevQuarterClose":53.02,"fiveDayClose":49.19,"twentyDayClose":51.78,"sixtyDayClose":52.9,"dividendPayoutRate":0.8394110571990734,"dividendFrequency":"Q","dividendGrowthYears":0,"fiveYearAvgDividendRate":0.04206805783252231},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EMA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-07","symbol":"EMA","fiscalQuarterEnding":"2026/06","expectedEps":0.51,"name":null,"time":"盤前","type":"earning","dateTimestamp":1786075200000,"reportTimeType":"pre","actualEps":0.5},{"date":"2026-08-03","symbol":"EMA","amount":0.7325,"announcedDate":"2026-07-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-03","defaultRemindTime":1785763800000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-03","currency":"CAD","dateTimestamp":1785729600000,"payDate":"2026-08-17"},{"market":"US","date":"2026-05-08","symbol":"EMA","fiscalQuarterEnding":"2026/03","expectedEps":0.89,"name":null,"time":"盤前","type":"earning","dateTimestamp":1778212800000,"reportTimeType":"pre","actualEps":1},{"date":"2026-05-01","symbol":"EMA","amount":0.7325,"announcedDate":"2026-04-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-01","defaultRemindTime":1777642200000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-15","payableDate":"2026-05-01","currency":"CAD","dateTimestamp":1777608000000,"payDate":"2026-05-15"},{"market":"US","date":"2026-02-23","symbol":"EMA","fiscalQuarterEnding":"2025/12","expectedEps":0.43,"name":null,"time":"盤前","type":"earning","dateTimestamp":1771822800000,"reportTimeType":"pre","actualEps":0.4}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EMA\",market:\"US\",,,undefined,":[{"executeDate":"2016-10-28","recordDate":"2016-11-01","paymentDate":"2016-11-15","value":0.3880294,"currency":"USD"},{"executeDate":"2025-08-01","recordDate":"2025-08-01","paymentDate":"2025-08-15","value":0.725,"currency":"CAD"},{"executeDate":"2025-10-31","recordDate":"2025-10-31","paymentDate":"2025-11-14","value":0.7325,"currency":"CAD"},{"executeDate":"2026-01-30","recordDate":"2026-01-30","paymentDate":"2026-02-13","value":0.7325,"currency":"CAD"},{"executeDate":"2026-05-01","recordDate":"2026-05-01","paymentDate":"2026-05-15","value":0.7325,"currency":"CAD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EMA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1778299200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EMA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EMA","date":"2026-09-18","current":22.101023,"percent":0.558282,"low":16.637027,"twenty":17.871551,"median":20.245144,"eighty":21.031403,"high":22.07626,"avg":19.830871,"sd":1.467509,"marketCap":15149228130.36},"quantilePoints":[{"date":"2025-05-30","current":19.76944,"twenty":19.76944,"median":19.76944,"eighty":19.76944,"marketCap":13505496352.43},{"date":"2025-06-06","current":19.324012,"twenty":19.535669,"median":19.692043,"eighty":19.76944,"marketCap":13350532994.37},{"date":"2025-06-13","current":19.308216,"twenty":19.137627,"median":19.324012,"eighty":19.722054,"marketCap":13371262392.6},{"date":"2025-06-20","current":19.245035,"twenty":19.160372,"median":19.387193,"eighty":19.674036,"marketCap":13211518175.96},{"date":"2025-06-27","current":19.308216,"twenty":19.224185,"median":19.382455,"eighty":19.560942,"marketCap":13348226238.04},{"date":"2025-07-03","current":19.469329,"twenty":19.242508,"median":19.399829,"eighty":19.679723,"marketCap":13533023992.92},{"date":"2025-07-11","current":19.753645,"twenty":19.282944,"median":19.43142,"eighty":19.706259,"marketCap":13611556279.78},{"date":"2025-07-18","current":19.592532,"twenty":19.308216,"median":19.502499,"eighty":19.712577,"marketCap":13439260670.95},{"date":"2025-07-25","current":20.116937,"twenty":19.317694,"median":19.614646,"eighty":19.767545,"marketCap":13920070443.21},{"date":"2025-08-01","current":20.552889,"twenty":19.356234,"median":19.663612,"eighty":19.931816,"marketCap":14004388886.88},{"date":"2025-08-08","current":20.884591,"twenty":19.383402,"median":19.706259,"eighty":20.124519,"marketCap":14315223696.17},{"date":"2025-08-15","current":20.686356,"twenty":19.389088,"median":19.714157,"eighty":20.375981,"marketCap":14241020029.57},{"date":"2025-08-22","current":21.111677,"twenty":19.401724,"median":19.753645,"eighty":20.511821,"marketCap":14434555399.62},{"date":"2025-08-29","current":20.468969,"twenty":19.420679,"median":19.785235,"eighty":20.581071,"marketCap":14130173597.74},{"date":"2025-09-05","current":20.484722,"twenty":19.429525,"median":19.883167,"eighty":20.585711,"marketCap":14060435241.25},{"date":"2025-09-12","current":20.283088,"twenty":19.441529,"median":20.015847,"eighty":20.549566,"marketCap":13928376571.28},{"date":"2025-09-19","current":19.923928,"twenty":19.461747,"median":20.073945,"eighty":20.542062,"marketCap":13714455884.59},{"date":"2025-09-26","current":20.585539,"twenty":19.495865,"median":20.087756,"eighty":20.542062,"marketCap":14040465233.16},{"date":"2025-10-03","current":21.108526,"twenty":19.558414,"median":20.183278,"eighty":20.617044,"marketCap":14341364686.36},{"date":"2025-10-10","current":21.127429,"twenty":19.601378,"median":20.281209,"eighty":20.758818,"marketCap":14318469638.17},{"date":"2025-10-17","current":21.666169,"twenty":19.623491,"median":20.300416,"eighty":20.797254,"marketCap":14653790731.95},{"date":"2025-10-24","current":21.757535,"twenty":19.646868,"median":20.374454,"eighty":20.916344,"marketCap":14770054950.94},{"date":"2025-10-31","current":21.360568,"twenty":19.663296,"median":20.386244,"eighty":21.06631,"marketCap":14513331426.12},{"date":"2025-11-07","current":21.272354,"twenty":19.674036,"median":20.41226,"eighty":21.097184,"marketCap":14296037747.86},{"date":"2025-11-14","current":17.374062,"twenty":19.601378,"median":20.386244,"eighty":21.06631,"marketCap":14568586353.81},{"date":"2025-11-21","current":17.212836,"twenty":19.441529,"median":20.374454,"eighty":21.041735,"marketCap":14368588864.66},{"date":"2025-11-28","current":17.407331,"twenty":19.394143,"median":20.301992,"eighty":21.030393,"marketCap":14577653448.13},{"date":"2025-12-05","current":16.921093,"twenty":19.311375,"median":20.282148,"eighty":21.003928,"marketCap":14257439118.84},{"date":"2025-12-12","current":16.693329,"twenty":19.18059,"median":20.230664,"eighty":20.983135,"marketCap":14234564864},{"date":"2025-12-19","current":17.167393,"twenty":17.900621,"median":20.102346,"eighty":20.957301,"marketCap":14657419004.37},{"date":"2025-12-26","current":17.216186,"twenty":17.458514,"median":20.073945,"eighty":20.944699,"marketCap":14789996894.17},{"date":"2026-01-02","current":17.370269,"twenty":17.373303,"median":20.0392,"eighty":20.932097,"marketCap":14871263471.89},{"date":"2026-01-09","current":17.43447,"twenty":17.368214,"median":19.923928,"eighty":20.903742,"marketCap":14773589152.84},{"date":"2026-01-16","current":17.439606,"twenty":17.353836,"median":19.83736,"eighty":20.887161,"marketCap":14748903694.51},{"date":"2026-01-23","current":17.57828,"twenty":17.358457,"median":19.76786,"eighty":20.862056,"marketCap":14967122519.73},{"date":"2026-01-30","current":17.452446,"twenty":17.36616,"median":19.731531,"eighty":20.822459,"marketCap":15149245081.41},{"date":"2026-02-06","current":17.639913,"twenty":17.358457,"median":19.706259,"eighty":20.792844,"marketCap":15150466223.22},{"date":"2026-02-13","current":17.632209,"twenty":17.329694,"median":19.687304,"eighty":20.780241,"marketCap":15197950382.19},{"date":"2026-02-20","current":18.01228,"twenty":17.336884,"median":19.662032,"eighty":20.776461,"marketCap":15461241242.05},{"date":"2026-02-27","current":19.370854,"twenty":17.349212,"median":19.603589,"eighty":20.77079,"marketCap":15419204876.87},{"date":"2026-03-06","current":19.860551,"twenty":17.357687,"median":19.614646,"eighty":20.758818,"marketCap":15772457447.89},{"date":"2026-03-13","current":20.172176,"twenty":17.364105,"median":19.663612,"eighty":20.731723,"marketCap":16126249798.12},{"date":"2026-03-20","current":19.982975,"twenty":17.371786,"median":19.706259,"eighty":20.697698,"marketCap":15868293252.05},{"date":"2026-03-27","current":19.866116,"twenty":17.374599,"median":19.676248,"eighty":20.661152,"marketCap":15623406729.11},{"date":"2026-04-02","current":20.186088,"twenty":17.375919,"median":19.706259,"eighty":20.620195,"marketCap":15797694590.77},{"date":"2026-04-10","current":20.433719,"twenty":17.383333,"median":19.710303,"eighty":20.603182,"marketCap":16095943521.79},{"date":"2026-04-17","current":20.225489,"twenty":17.405284,"median":19.739002,"eighty":20.583555,"marketCap":16062393790.34},{"date":"2026-04-24","current":20.11598,"twenty":17.412759,"median":19.756565,"eighty":20.571074,"marketCap":16011506016.84},{"date":"2026-05-01","current":20.349038,"twenty":17.435497,"median":19.769087,"eighty":20.551228,"marketCap":16279588937.86},{"date":"2026-05-08","current":20.003663,"twenty":17.442174,"median":19.801031,"eighty":20.543322,"marketCap":15972071463.03},{"date":"2026-05-15","current":20.526748,"twenty":17.453473,"median":19.863334,"eighty":20.551228,"marketCap":15993082457.11},{"date":"2026-05-22","current":20.821212,"twenty":17.457768,"median":19.873689,"eighty":20.574777,"marketCap":16159791825.34},{"date":"2026-05-29","current":20.784047,"twenty":17.458514,"median":19.874498,"eighty":20.606796,"marketCap":16109213261.77},{"date":"2026-06-05","current":20.455276,"twenty":17.46015,"median":19.931505,"eighty":20.606796,"marketCap":15744335184.44},{"date":"2026-06-12","current":20.798341,"twenty":17.481546,"median":19.990575,"eighty":20.612514,"marketCap":15890994194.64},{"date":"2026-06-18","current":20.901261,"twenty":17.493192,"median":20.015847,"eighty":20.650154,"marketCap":15823421326.33},{"date":"2026-06-26","current":21.595968,"twenty":17.496103,"median":20.061717,"eighty":20.767009,"marketCap":16281617755.86},{"date":"2026-07-02","current":21.507343,"twenty":17.504259,"median":20.064683,"eighty":20.784032,"marketCap":16222688501.02},{"date":"2026-07-10","current":21.544508,"twenty":17.526194,"median":20.082188,"eighty":20.821212,"marketCap":16271827884.13},{"date":"2026-07-17","current":21.936175,"twenty":17.541814,"median":20.087829,"eighty":20.898969,"marketCap":16718811747.19},{"date":"2026-07-24","current":22.07626,"twenty":17.564926,"median":20.116937,"eighty":20.951,"marketCap":16761941188.16},{"date":"2026-07-31","current":21.66744,"twenty":17.586675,"median":20.124404,"eighty":21.004011,"marketCap":16545696607.24},{"date":"2026-08-07","current":20.666833,"twenty":17.604226,"median":20.156816,"eighty":21.026741,"marketCap":15758445214.07},{"date":"2026-08-14","current":21.122954,"twenty":17.619883,"median":20.180562,"eighty":21.040346,"marketCap":15758083883.88},{"date":"2026-08-21","current":21.131815,"twenty":17.635291,"median":20.20188,"eighty":21.05159,"marketCap":15955602988.26},{"date":"2026-08-28","current":20.499692,"twenty":17.645049,"median":20.225489,"eighty":21.044992,"marketCap":15379168560.24},{"date":"2026-09-04","current":20.473108,"twenty":17.659944,"median":20.257815,"eighty":21.043803,"marketCap":15442660903.12},{"date":"2026-09-11","current":20.227938,"twenty":17.708223,"median":20.275847,"eighty":21.041773,"marketCap":15223834714.33},{"date":"2026-09-18","current":20.381538,"twenty":17.871551,"median":20.245144,"eighty":21.031403,"marketCap":15149228130.36}],"updateTime":1789918695563},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EMA\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2668183959","title":"數十名患者起訴司美格魯肽製造商","url":"https://stock-news.laohu8.com/highlight/detail?id=2668183959","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668183959?lang=zh_tw&edition=fundamental","pubTime":"2026-09-20 15:28","pubTimestamp":1789889280,"startTime":"0","endTime":"0","summary":"近日，美国数十人因在服药期间患上眼疾而起诉司美格鲁肽的制造商诺和诺德。这名患者在就医时表示，服用司美格鲁肽治疗2型糖尿病长达6个月，医生要求其立即停药，以保护剩余的视力。自2025年以来，处理人身伤害案的律师事务所魏茨与卢森伯格律师事务所代表芬内尔在内的患者，在新泽西州州法院提起了90多起诉讼，这些患者在服用司美格鲁肽期间患上NAION，正在向诺和诺德索赔。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2026-09-20/doc-inisnhca6675853.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-20/doc-inisnhca6675853.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["EMA","BK4081","AOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662639772","title":"伯維（ABBV）向EMA遞交Skyrizi克羅恩病治療上市申請","url":"https://stock-news.laohu8.com/highlight/detail?id=2662639772","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662639772?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 16:56","pubTimestamp":1787821007,"startTime":"0","endTime":"0","summary":"Skyrizi此前已经在银屑病、银屑病关节炎等多个自身免疫疾病领域拿到欧洲地区的获批资质，如若本次克罗恩病适应症顺利获批，将进一步拓宽该产品在欧洲炎症性肠病赛道的市场空间。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250107/ZDBhOTg3YTMxNzM2MjM3OTI3ODI2.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZDBhOTg3YTMxNzM2MjM3OTI3ODI2.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305377","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2087621335.USD","JDOC","LU0472753341.HKD","SG9999001440.SGD","AGNG","LU0661504455.SGD","LU0058720904.USD","BK4559","LU1585245621.USD","FTXH","LU1839511570.USD","IE000F7OJYX1.SGD","LU2023251221.USD","FHLC","PJP","ABBV","MEDX","LU2237443622.USD","EMA","SG9999011175.SGD","LU0198837287.USD","IPOS","LU0114720955.EUR","LU2089283258.USD","LU2133065610.SGD","RXL","LU2125909593.SGD","LU1267930573.SGD","IE0004445239.USD","PPH","LU1732799900.SGD","XLV","IXJ","LU0128525929.USD","LU1236620750.USD","LU2125909247.SGD","IE00BLSP4239.USD","BK4533","LU0417517546.SGD","TRUH","VHT","IYH","LU0234572021.USD","LU0882574055.USD","LU0965508806.USD","LU1989771016.USD","LU0985320562.USD","LU0289739699.SGD","GLAM","LU1236620834.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662200130","title":"中化國際EMA項目投產","url":"https://stock-news.laohu8.com/highlight/detail?id=2662200130","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662200130?lang=zh_tw&edition=fundamental","pubTime":"2026-08-25 10:09","pubTimestamp":1787623784,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661483293","title":"分析師：比特幣已觸及長期下行趨勢線及 21 個月 EMA 均線，站穩當前阻力線方能確認漲勢","url":"https://stock-news.laohu8.com/highlight/detail?id=2661483293","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661483293?lang=zh_tw&edition=fundamental","pubTime":"2026-08-21 21:18","pubTimestamp":1787318280,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，加密分析师 Rekt Capital 发布比特币技术图表分析指出，比特币正遭遇宏观下行趋势线阻力，该趋势线与 21 个月 EMA 均线拟合。Rekt Capital 认为，如果比特币在这个拟合的阻力区域受阻，那么可能在 50 个月 EMA 均线处（紫色）获得支撑。总体而言，比特币需要将这两个宏观 EMA 重新转化为新的支撑位，并突破宏观下行趋势线，以确认新一轮牛市。Rekt Capital 系资深加密技术分析师，在 X 平台拥有 56 万粉丝。 ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2284491","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["YBTC","BITX","CBTJ","BTC.USD.HKCC","BTCZ","IBIT","BITC","BTC.USD.CC","BTCO","MAXI","BTYB","BTCI","BTRN","MBTmain","STCE","09042","BTFX","BTGD","EMA","MSBT","BITI","BRRR","MSTU","NGHT","HECO","WGMI","BETH","BITQ","FBTC","GDLC","BKCH","BEGS","ARKY","BETE","03008","HODL","GBTC","DAPP","BITU","CRPT","OOQB","NCIQ","BITW","SMST","03439","LFGY","BTCL","BTF","YBIT","SBIT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659183413","title":"奧麥羅斯2026財年第二季度業績：YARTEMLEA推動運營實現收支平衡","url":"https://stock-news.laohu8.com/highlight/detail?id=2659183413","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659183413?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 04:18","pubTimestamp":1786565932,"startTime":"0","endTime":"0","summary":"Omeros公布2026财年第二季度产品销售净额为2850万美元，高于去年同期的零，主要得益于YARTEMLEA总收入达到3220万美元，较第一季度增长190%。按GAAP计算的净利润为1320万美元，每股基本收益为0.18美元，但其中包含1150万美元的非现金公允价值收益；非GAAP调整后净利润为180万美元。经营活动产生现金410万美元，而在7月份完成6020万美元的可转换票据回购之前，截至6月底的现金及短期投资总额为1.32亿美元。","market":"sg","thumbnail":"https://resource.tradingkey.com/cdn/images/article/news/stock5.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cdn/images/article/news/stock5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/earnings/262100447-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU0949170772.SGD","LU1894683348.USD","BK4170","LU0203347892.USD","LU0942090050.USD","LU0553294199.USD","LU1894683264.USD","CHMP","BK4588","BK4081","LU0868494617.USD","LU0738911758.USD","OMER","LU0545039389.USD","LU0203345920.USD","LU2637428348.USD","LU0661504455.SGD","LU2346227817.USD","LU2500361329.USD","SG9999001440.SGD","CMS","BK4585","LU0868494708.USD","BK4208","LU1003077747.HKD","EMA","NTAP","CEO","BK4087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657648031","title":"Emera（EMA）上半年調整後淨利潤增至6.27億加元、淨收入降至6.67億加元","url":"https://stock-news.laohu8.com/highlight/detail?id=2657648031","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657648031?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 19:34","pubTimestamp":1786102483,"startTime":"0","endTime":"0","summary":"金吾财讯 | 北美能源巨头Emera 公布2026年第二季度及上半年财务业绩。2026年二季度，Emera实现调整后净利润2.12亿加元，较上年同期的2.36亿加元有所放缓；净利润为1.05亿加元。2026年上半年，公司调整后净利润达到6.27亿加元，高于2025年上半年的6.15亿加元。期内净收入为6.67亿加元，低于去年同期的7.18亿加元。展望未来，公司预计，2026年调整后每股收益增长将超越其5%-7%的年度目标区间高位，公司重申截至2030年维持5%-7%的复合年均增长承诺。","market":"other","thumbnail":"https://static.szfiu.com/news/20250107/NDEzNGMxNzgxNjk0YjcxNTczNmY1MTEwODUxNDQzMTc3Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NDEzNGMxNzgxNjk0YjcxNTczNmY1MTEwODUxNDQzMTc3Ng==.jpg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303564","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148281703","title":"財報前瞻｜Emera Inc.本季度營收預計增15.89%，機構觀點偏謹慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1148281703","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148281703?lang=zh_tw&edition=fundamental","pubTime":"2026-07-31 08:42","pubTimestamp":1785458557,"startTime":"0","endTime":"0","summary":"Emera Inc.将于2026年08月07日盘前发布第二季度财报，市场预期营收增长而利润承压，投资者关注盈利质量与现金流稳定性。一致预期显示，本季度Emera Inc.营收为20.29亿加元，同比增长15.89%；调整后每股收益为0.49加元，同比下降24.17%；EBIT为4.73亿加元，同比增长1.23%，上一季度未披露针对本季度的明确量化指引。上季度公司实现营收28.13亿加元，同比增长5.12%；毛利率50.20%；归属于母公司股东的净利润5.82亿加元，净利率20.69%；调整后每股收益同比增长7.00%，净利润环比增长568.97%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜Emera Inc.本季度营收预计增15.89%，机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654001188","title":"瑞博生物-B：核心產品VORTOSIRAN針對SPAF的2B期臨床試驗獲EMA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2654001188","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654001188?lang=zh_tw&edition=fundamental","pubTime":"2026-07-28 19:59","pubTimestamp":1785239982,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBJ","EMA","IBBQ","BK4081","PSYK","BMED","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653608566","title":"歐洲藥品管理局（EMA）：阿斯利康(AZN.US)已撤回其重磅免疫藥物Imfinzi在歐盟的擴展適應症申請。","url":"https://stock-news.laohu8.com/highlight/detail?id=2653608566","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653608566?lang=zh_tw&edition=fundamental","pubTime":"2026-07-24 18:07","pubTimestamp":1784887647,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2237443465.HKD","LU1267930573.SGD","BK4007","LU0889565916.HKD","BK4081","LU0058720904.USD","AZN","LU2237443895.HKD","LU2089984988.USD","LU0128525929.USD","LU0320765992.SGD","BK4588","LU0109394709.USD","LU0289739699.SGD","LU0708994859.HKD","EMA","BK4568","LU0432979614.USD","LU2456880835.USD","LU0310800379.SGD","LU2237443978.SGD","AZNH","LU2417539215.USD","LU2462157665.USD","LU2468319806.SGD","LU2237443549.SGD","LU2237443622.USD","IE00B3T34201.USD","LU2237443382.USD","LU2236285917.USD","BK4585","LU0029864427.USD","LU1829250122.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647037238","title":"Rocket Lab股價站穩200日EMA上方：獲NASA合同後是否值得買入？","url":"https://stock-news.laohu8.com/highlight/detail?id=2647037238","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647037238?lang=zh_tw&edition=fundamental","pubTime":"2026-06-29 21:09","pubTimestamp":1782738540,"startTime":"0","endTime":"0","summary":"Rocket Lab股价周一盘前交易时段上涨，此前该公司宣布将收购卫星通信运营商Iridium，交易价值约80亿美元。这一消息叠加近期获得的NASA发射合同，为股价提供了技术面支撑。　　从技术走势来看，Rocket Lab股价在6月25日跌至80.69美元的低点后获得支撑，目前盘前交易于90美元附近，成功站稳200日指数移动平均线上方。　　上周，NASA宣布选择Rocket Lab执行三项Electron火箭发射任务，用于PolSIR和TSIS-2科学任务，预计于2027年初启动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-29/doc-inifauhn5315358.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["EMA","300785","NASA","BK4081","BK0217"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645409710","title":"恒瑞醫藥(600276.SH)：瑞維魯胺片上市許可申請獲EMA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2645409710","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645409710?lang=zh_tw&edition=fundamental","pubTime":"2026-06-22 16:38","pubTimestamp":1782117505,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司收到了欧洲药品管理局(European Medicines Agency，简称“EMA”)的通知,EMA正式确认并受理公司递交的瑞维鲁胺片的上市许可申请，这是公司首个自主研发的创新药向欧盟递交上市申请。该药品适用于联合雄激素剥夺治疗(ADT)，治疗高瘤负荷的转移性激素敏感性前列腺癌(mHSPC)成年男性患者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456886.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2097828714.EUR","LU2543165471.USD","600276","LU1997244956.HKD","LU2097828474.EUR","LU1969619763.USD","LU2148510915.USD","BK0188","LU2328871848.SGD","LU0359202008.SGD","LU1064131003.USD","LU1146622755.USD","LU2097828805.USD","BK0183","LU1655091616.SGD","LU1820825898.SGD","LU0405327148.USD","EMA","BK0028","LU1023057109.AUD","01276","LU1328615791.USD","LU2495084118.USD","LU1255011170.USD","LU2580892862.HKD","LU2488822045.USD","LU1997245177.USD","LU1781817850.SGD","LU2580892789.USD","BK4081","LU1997245094.SGD","BK0012","IPOS","BK0196","BK0060","LU0359201612.USD","LU1580142542.USD","LU2289578879.USD","BK0239","LU0405327494.USD","LU0359201885.HKD","LU2097828631.EUR","LU1064130708.USD","LU2097828557.USD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178964593","title":"新聞稿：CosmoFarm公布2026年第二季度創紀錄營收超1500萬美元，年化運行率超6000萬美元；新增超80家藥房並擴展AI自動化與設施產能","url":"https://stock-news.laohu8.com/highlight/detail?id=1178964593","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178964593?lang=zh_tw&edition=fundamental","pubTime":"2026-06-19 03:35","pubTimestamp":1781811307,"startTime":"0","endTime":"0","summary":"Cosmos Health Inc.今日宣布，其全资子公司CosmoFarm S.A.在2026年第二季度实现了超过1500万美元的创纪录营收，这相当于超过6000万美元的年化运行率。Cosmos Health是一家业务多元化、垂直整合的全球医疗健康集团。在此期间，CosmoFarm在其分销网络中新增了超过80家药房，延续了强劲的客户增长势头，这使其已成为大雅典地区领先的医药批发商之一。为了支持这一加速增长，Cosmos Health正在增加CosmoFarm的资本支出，投资于新的机器人自动化与人工智能系统，以优化采购、库存管理和订单履行。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","AIPO","BK4175","R","EMA","BK4081","ARTY","CHAT","AGIX","COSM","BK4022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637806473","title":"從跟隨者到定價者：加密市場的角色正在反轉","url":"https://stock-news.laohu8.com/highlight/detail?id=2637806473","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637806473?lang=zh_tw&edition=fundamental","pubTime":"2026-05-21 12:09","pubTimestamp":1779336566,"startTime":"0","endTime":"0","summary":" 加密平台在 CBRS 上市前成功实现了精准的先期定价，这表明 Crypto 正凭借创新机制，逐步从传统金融的跟随者转变为全球资产的新定价中枢。 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2266266","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBRS","EMA","FAZ","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185761853","title":"財報前瞻｜Emera Inc.本季度營收預計增35.49%，盈利質量成看點","url":"https://stock-news.laohu8.com/highlight/detail?id=1185761853","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185761853?lang=zh_tw&edition=fundamental","pubTime":"2026-05-01 08:17","pubTimestamp":1777594630,"startTime":"0","endTime":"0","summary":"Emera Inc.将于2026年05月08日公布最新季度业绩，市场关注营收增速与成本控制的落地情况。根据一致预期，本季度Emera Inc.营收预计为30.09亿加元，同比增长35.49%；调整后每股收益预计为1.15加元，同比增长15.55%；息税前利润预计为7.02亿加元，同比增长7.05%；当前一致预期未提供本季度毛利率及净利润或净利率的具体预测。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Emera Inc.本季度营收预计增35.49%，盈利质量成看点","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627213629","title":"羅氏獲歐洲監管機構反饋後，啓動Elevidys基因療法新研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2627213629","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627213629?lang=zh_tw&edition=fundamental","pubTime":"2026-04-16 20:44","pubTimestamp":1776343440,"startTime":"0","endTime":"0","summary":"罗氏公司周四宣布，在收到欧洲药品监管机构的反馈后，将针对其基因疗法 Elevidys 启动一项晚期临床试验。该疗法用于治疗杜氏肌营养不良症，由罗氏与美国 Sarepta Therapeutics 公司合作研发。此前，因两例患者死亡事件与该疗法相关而引发审查，这款药物去年未能获得欧洲药品管理局的批准。Elevidys 目前已在 9 个国家获批用于可自主行走、确诊携带 DMD 基因突变的男孩，其中包括美国。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-16/doc-inhuszrw2800982.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624593383","title":"港股異動 | 和譽-B(02256)盤中漲近10% FGFR4抑制劑依帕戈替尼獲EMA授予孤兒藥資格","url":"https://stock-news.laohu8.com/highlight/detail?id=2624593383","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624593383?lang=zh_tw&edition=fundamental","pubTime":"2026-04-01 15:57","pubTimestamp":1775030256,"startTime":"0","endTime":"0","summary":"消息面上，和誉宣布，其自主研发的高选择性小分子FGFR4抑制剂依帕戈替尼已获得欧洲药品管理局授予的孤儿药资格，用于治疗肝细胞癌。目前，依帕戈替尼正在全球多地开展临床研究，此次获EMA授予ODD，将为该产品在欧洲的临床开发、注册申报与商业化进程提供有力支持。除本次获得EMA孤儿药资格外，依帕戈替尼此前还分别获得了美国食品药品监督管理局授予的ODD和快速通道资格认定，以及中国国家药品监督管理局授予的突破性疗法认定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423918.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4081","BK4588","EMA","LU2476274308.USD","02256","IE00B543WZ88.USD","BK1161","VXUS","LU2476274720.SGD","IE00B5MMRT66.SGD","BK4585","IE00BPRC5H50.USD","LU2778985437.USD","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623581546","title":"和譽-B(02256)：FGFR4抑制劑依帕戈替尼獲EMA授予孤兒藥資格，用於治療肝細胞癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2623581546","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623581546?lang=zh_tw&edition=fundamental","pubTime":"2026-03-31 20:32","pubTimestamp":1774960347,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B 发布公告，公司附属公司上海和誉生物医药科技有限公司宣布，其自主研发的高选择性口服小分子FGFR4抑制剂依帕戈替尼已获得欧洲药品管理局授予的孤儿药资格，用于治疗肝细胞癌。目前，依帕戈替尼正在全球多地开展临床研究，此次获EMA授予ODD，将为该产品在欧洲的临床开发、注册申报与商业化进程提供有力支持。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423262.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B543WZ88.USD","IE00BPRC5H50.USD","LU2488822045.USD","LU2778985437.USD","EMA","BK4081","IE00B5MMRT66.SGD","BK1161","02256","LU2476274720.SGD","LU2476274308.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":17,"code":"91000000","status":"200"}]}}